Physician profile
Samir E Hage
NPI 1821059924
$639,717.00
in general payments reported to CMS, 2019-2025
21 companies · $115K in 2025
The $115K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $34K · 2021: $62K · 2022: $86K · 2023: $142K · 2024: $146K · 2025: $115K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $341K · Travel and Lodging: $34K · Food and Beverage: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $341,466.00 |
| Travel and Lodging | $33,573.93 |
| Food and Beverage | $19,392.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $638,113.54 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Hologic Sales and Service, LLC | $354.37 | 2023-2025 | Acessa Provu System, Novasure, Aptima |
| Abbvie INC. | $220.70 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $126.79 | 2023 | |
| Amag Pharmaceuticals, INC. | $125.00 | 2019 | |
| Caldera Medical, INC | $113.92 | 2024 | Desara |
| Coopersurgical, INC. | $109.49 | 2020-2025 | Paragard T 380a, Endosee |
| Organon LLC | $105.64 | 2022-2025 | Nexplanon |
| Astellas Pharma US INC | $81.09 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $64.94 | 2023-2025 | |
| Sage Therapeutics, LLC | $53.66 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $44.05 | 2019-2022 | |
| Boston Scientific Corporation | $37.99 | 2019-2025 | Bulkamid |
| Bayer Healthcare Pharmaceuticals INC. | $29.63 | 2019 | |
| Myovant Sciences INC. | $28.54 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $23.43 | 2025 | |
| Agile Therapeutics, INC. | $18.56 | 2023 | Twirla |
| Exeltis, USA INC. | $18.27 | 2025 | Slynd |
| Merck Sharp & Dohme LLC | $17.51 | 2019 | |
| Meditrina | $16.41 | 2023 | |
| Allergan, INC. | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Hage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.